TY - JOUR
T1 - Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen
AU - Washizaki, Ayaka
AU - Murayama, Asako
AU - Murata, Megumi
AU - Kiyohara, Tomoko
AU - Yato, Keigo
AU - Yamada, Norie
AU - Aly, Hussein Hassan
AU - Tanaka, Tomohisa
AU - Moriishi, Kohji
AU - Nishitsuji, Hironori
AU - Shimotohno, Kunitada
AU - Goh, Yasumasa
AU - Ishii, Ken J.
AU - Yotsuyanagi, Hiroshi
AU - Muramatsu, Masamichi
AU - Ishii, Koji
AU - Takahashi, Yoshimasa
AU - Suzuki, Ryosuke
AU - Akari, Hirofumi
AU - Kato, Takanobu
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Although the current hepatitis B (HB) vaccine comprising small-HBs antigen (Ag) is potent and safe, attenuated prophylaxis against hepatitis B virus (HBV) with vaccine-escape mutations (VEMs) has been reported. We investigate an HB vaccine consisting of large-HBsAg that overcomes the shortcomings of the current HB vaccine. Yeast-derived large-HBsAg is immunized into rhesus macaques, and the neutralizing activities of the induced antibodies are compared with those of the current HB vaccine. Although the antibodies induced by the current HB vaccine cannot prevent HBV infection with VEMs, the large-HBsAg vaccine-induced antibodies neutralize those infections. The HBV genotypes that exhibited attenuated neutralization via these vaccines are different. Here, we show that the HB vaccine consisting of large-HBsAg is useful to compensate for the shortcomings of the current HB vaccine. The combined use of these HB vaccines may induce antibodies that can neutralize HBV strains with VEMs or multiple HBV genotypes.
AB - Although the current hepatitis B (HB) vaccine comprising small-HBs antigen (Ag) is potent and safe, attenuated prophylaxis against hepatitis B virus (HBV) with vaccine-escape mutations (VEMs) has been reported. We investigate an HB vaccine consisting of large-HBsAg that overcomes the shortcomings of the current HB vaccine. Yeast-derived large-HBsAg is immunized into rhesus macaques, and the neutralizing activities of the induced antibodies are compared with those of the current HB vaccine. Although the antibodies induced by the current HB vaccine cannot prevent HBV infection with VEMs, the large-HBsAg vaccine-induced antibodies neutralize those infections. The HBV genotypes that exhibited attenuated neutralization via these vaccines are different. Here, we show that the HB vaccine consisting of large-HBsAg is useful to compensate for the shortcomings of the current HB vaccine. The combined use of these HB vaccines may induce antibodies that can neutralize HBV strains with VEMs or multiple HBV genotypes.
UR - http://www.scopus.com/inward/record.url?scp=85137255091&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137255091&partnerID=8YFLogxK
U2 - 10.1038/s41467-022-32910-z
DO - 10.1038/s41467-022-32910-z
M3 - Article
C2 - 36064848
AN - SCOPUS:85137255091
SN - 2041-1723
VL - 13
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 5207
ER -
